The US is the largest maker for Indian drugmakers, but after this imposition, if the company is making a pharmaceutical manufacturing plant in America or it is under construction, they will be safe from large tariffs. and it includes many other tariffs on different things.
India sold $3.6 billion (₹31,626 crore) worth of medicines to the US in 2024, and another $3.7 billion (₹32,505 crore) just in the first half of 2025.
Indian companies like Dr Reddy’s, Sun Pharma, Lupin, and Aurobindo have done well in the US because they offer cheaper generic medicines.
Recently, President Trump announced new tariffs mainly targeting expensive branded and patented drugs made by big global companies. But there’s still worry that Indian-made complex generics and specialty medicines might also be affected.
Right now, Indian pharmaceutical exports to the US are already facing a 50% tariff. Trump says this includes a 25% extra charge because India continues to buy oil from Russia.
SOURCE: HINDUSTAN TIMES AND TRUTH SOCIAL
Comments